¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Leukemia Inhibitory Factor Receptor alpha Subunit"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ
  • peripheral inhibitory field
    ¸»ÃʾïÁ¦¿µ¿ª
  • reticular inhibitory area
    ±×¹°Ã¼¾ïÁ¦ºÎÀ§
  • aplastic leukemia
    °ñ¼ö¹«Çü¼º¹éÇ÷º´
  • acute lymphocytic leukemia
    ±Þ¼º¸²ÇÁ±¸¹éÇ÷º´
  • acute myelocytic leukemia
    ±Þ¼º°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • acute promyelocytic leukemia
    ±Þ¼ºÀü°ñ¼ö¼¼Æ÷¹éÇ÷º´, ±Þ¼ºÇ²°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • acute undifferentiated leukemia
    ±Þ¼º¹ÌºÐÈ­¹éÇ÷º´
  • adult T-cell leukemia/lymphoma
    ¼ºÀÎT¼¼Æ÷¹éÇ÷º´/¸²ÇÁÁ¾
  • aleukemic leukemia
    ¹«¹éÇ÷¼º¹éÇ÷º´
  • chloroma leukemia
    ³ì»öÁ¾¹éÇ÷º´
  • chronic lymphoblastic leukemia/small lymphocytic lymphoma
    ¸¸¼º¸²ÇÁ¸ð±¸¹éÇ÷º´/¼Ò¸²ÇÁ±¸¸²ÇÁÁ¾
  • chronic lymphocytic leukemia
    ¸¸¼º¸²ÇÁ±¸¹éÇ÷º´
  • chronic myelocytic leukemia
    ¸¸¼º°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • eosinophilic leukemia
    È£»ê±¸¹éÇ÷º´
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • psychological factor
    ½É¸®¿ä¼Ò
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½ºÀÎÀÚ
  • risk factor
    À§ÇèÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • inhibitory postsynaptic potential
    ¾ïÁ¦½Ã³ÀÈÄÀüÀ§, ¾ïÁ¦¿¬Á¢ÈÄÀüÀ§
  • acute undifferentiated leukemia
    ±Þ¼º¹ÌºÐÈ­¹éÇ÷º´
  • aleukemic leukemia
    ¹«¹éÇ÷¼º¹éÇ÷º´
  • aplastic leukemia
    °ñ¼ö¹«Çü¼º¹éÇ÷º´
  • chloroma leukemia
    ³ì»öÁ¾¹éÇ÷º´
  • granulocytic leukemia
    (¢¡myelogenous leukemia) °ñ¼ö¹éÇ÷º´
  • hairy cell leukemia
    Åм¼Æ÷¹éÇ÷º´
  • leukemia
    ¹éÇ÷º´
  • leukopenic leukemia
    (¢¡aleukemic leukemia) ¹«¹éÇ÷¼º¹éÇ÷º´
  • lymphatic leukemia
    (¢¡lymphoblastic leukemia) ¸²ÇÁ¸ð±¸¹éÇ÷º´
  • lymphoblastic leukemia
    ¸²ÇÁ¸ð±¸¹éÇ÷º´
  • lymphocytic leukemia
    (¢¡lymphoblastic leukemia) ¸²ÇÁ¸ð±¸¹éÇ÷º´
  • lymphosarcoma cell leukemia
    ¸²ÇÁÀ°Á¾¼¼Æ÷¹éÇ÷º´
  • megakaryocytic leukemia
    °ÅÇÙ±¸¹éÇ÷º´, °Å´ëÇÙ¼¼Æ÷¹éÇ÷º´
  • monocytic leukemia
    ´ÜÇÙ±¸¹éÇ÷º´
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • T cell leukemia
    T¼¼Æ÷(¹éÇ÷º´
  • acute granulocytic leukemia
    ±Þ¼º °ú¸³±¸(¼º) ¹éÇ÷º´(¡­Î¨í£Ï¹àõÛÜúìÜ»).
  • acute granulocytic leukemia
    ±Þ¼º °ú¸³±¸(¼º) ¹éÇ÷º´(??ËöË´ËÛËÑÌ´ËÓ).
  • acute leukemia
    ±Þ¼º ¹éÇ÷º´(¡­ÛÜúìÜ»).
  • acute monocytic leukemia
    ±Þ¼º ´Ü±¸(¼º) ¹éÇ÷º´(?ËÀË´ËÛËÑÌ´ËÓ).
  • acute myeloblastic leukemia
    ±Þ¼º °ñ¼ö¸ð¼¼Æ÷¼º ¹éÇ÷º´.
  • acute myeloblastic leukemia
    ±Þ¼º °ñ¼ö¸ð¼¼Æ÷¼º ¹éÇ÷º´.
  • acute myelocytic leukemia =AML
    ±Þ¼º °ñ¼ö±¸¼º ¹éÇ÷º´.
  • acute myelogenous leukemia
    ±Þ¼º °ñ¼ö¼º ¹éÇ÷º´(¡­ÍéâÐàõÛÜúìÜ»).
  • acute myelogenous leukemia
    ±Þ¼º °ñ¼ö¼º ¹éÇ÷º´(?Ë­ËàËÛËÑÌ´ËÓ).
  • acute myelomonocytic leukemia
    ±Þ¼º °ñ¼ö´Ü±¸ ¹éÇ÷º´
  • acute undifferentiated leukemia
    ±Þ¼º ¹ÌºÐÈ­¼º ¹éÇ÷º´
  • adult T Cell leukemia virus
    ¼ºÀÎ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • adult T cell leukemia virus (HTLV)
    ¼ºÀÎT¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • adult t-cell leukemia/lymphoma
    ¼º¼÷ T-¼¼Æ÷ ¹éÇ÷º´/¸²ÇÁÁ¾(à÷âÙ¡­á¬øà ÛÜúìÜ»/¡­ðþ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • inhibitory postsynaptic potential = IPSP
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory synapse
    ¾ïÁ¦¼º ½Ã³³½º.
  • inhibitory synapse
    ¾ïÁ¦¼º(åäð¤àõ) ½Ã³³½º.
  • inhibitory transmitter
    ¾ïÁ¦¼º Àü´Þ¹°Áú.
  • inhibitory zone
    ¾ïÁ¦¹üÀ§(åäð¤ÛôêÌ).
  • minimal inhibitory concentration
    ÃÖÀú¹ßÀ°ÀúÁö³óµµ(õÌî¸Û¡ëÀðæò­ÒØöô).
  • minimum inhibitory concentration
    ÃÖ¼Ò¹ßÀ°ÀúÁö³óµµ(õÌá³Û¡ëÀîÁò­ÒØöô).
  • minimum inhibitory concentration
    ÃÖ¼Ò¾ïÁ¦³óµµ
  • minimum inhibitory concentration
    ÃÖ¼Ò¹ßÀ°ÀúÁö³óµµ(̧ËÛËÑËôËøÌ¤ËÀ̬).
  • minimum inhibitory dose
    ÃÖ¼Ò¾ïÁ¦·®(¡­åäð¤åÖ).
  • peripheral inhibitory field
    ¸»ÃʾïÁ¦¾ß(¡­åäð¤å¯).
  • reticular inhibitory area
    ¸Á»óü¾ïÁ¦ºÎÀ§(ØÑ ßÒô÷åäð¤Ý»êÈ).
  • col factor(»ýÈ­) cÀÌ ÀÎÀÚ colicin factor
    Äݸ®½ÅÀÎÀÚ.
  • lupus erythematosus factor = LE factor
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­)
  • time, dose and fractionation factor, TDF factor
    ½Ã°£¼±·®ºÐÇÒÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Fc receptor
    Fc ¼ö¿ëü(áôé»ô÷)
  • floating receptor model
    ºÎÀ¯ ¼ö¿ëü(Ý©ë´áôé»ô÷) ¸ðµ¨
  • glucocorticoid receptor
    ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀÌµå ¼ö¿ëü(áôé»ô÷)
  • H1 receptor
    H1 ¼ö¿ëü(áôé»ô÷)
  • H2 receptor
    H2 ¼ö¿ëü(áôé»ô÷)
  • LDL receptor
    LDL ¼ö¿ëü(áôé»ô÷)
  • ligand-receptor internalization
    ¸®°£µå-¼ö¿ëü(áôé»ô÷) ³»ÀÔ(Ò®ìý)
  • mineralocorticoid receptor
    ±¤Áú(ÎÎòõ) ÄÚ¸£Æ¼ÄÚÀÌµå ¼ö¿ëü(áôé»ô÷)
  • mobile receptor model
    À̵¿¼ö¿ëü(ì¹ÔÑáôé»ô÷) ¸ðµ¨
  • muscarinic receptor
    ¹«½ºÄ«¸°¼ö¿ëü(áôéÄô÷)
  • nicotinic receptor
    ´ÏÄÚÆ¾¼ö¿ëü(â¥é»ô÷)
  • opiate receptor
    ¾ÆÆíÁ¦(ð¥) ¼ö¿ëü(áôé»ô÷)
  • opioid receptor
    ¾ÆÆí°è(ͧ) ¾à¹°¼ö¿ëü(å·Úªáôé»ô÷)
  • receptor
    ¼ö¿ëü(áôé»ô÷)
  • receptor destroying enzyme
    ¼ö¿ëü ÆÄ±«È¿¼Ò(áôé»ô÷÷òÎÕý£áÈ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PAF paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl...
SF Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f...
TF free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ...
ANF alpha-naphthoflavone; American Nurses' Foundation; antineuritic factor; antinuclear factor; atrial n...
PIF   1) Proliferation Inhibitory Factor
  2) Prolactin release Inhibiting Factor...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
NMDAR1 N-methyl- D-aspartate receptor subunit 1
3 alpha-diol alpha-Androstan-3 alpha, 17 beta-diol
ITIM Immuno-receptor Tyrosine-based Inhibitory Motif
KIR Killer Inhibitory Receptor
KIR Killer cell inhibitory receptor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • inhibitory afferent input
    ¾ïÁ¦¼º ±¸½É¼º ÀÔ·Â
  • inhibitory contribution
    ¾ïÁ¦¼º ºÐÆ÷
  • inhibitory hormone
    ¾ïÁ¦ È£¸£¸ó
    Ç¥Àû ±â°ü¿¡ ´ëÇÏ¿© ¾ïÁ¦ÀûÀ¸·Î ÀÛ¿ëÇϴ ȣ¸£¸ó.
  • inhibitory input
    ¿ªÁ¦¼º ÀÔ·Â
  • inhibitory interneuron
    ¾ïÁ¦ °³Àç ´º¿ì·±
  • inhibitory output cell
    ¾ïÁ¦ Ãâ·Â ¼¼Æ÷
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄ Àü¾Ð
    ¾ïÁ¦¼º ±¸½É·Î¿¡ ÀÏÁ¦È÷ Ãæµ¿ÀÌ °¡ÇØÁú ¶§ ½Ã³À½º ÈÄ ´º·Ð¿¡ ¹ßÇàÇÏ´Â ¸·ÀüÀ§ÀÇ Àϰú¼º °úºÐ±ØÀ̸ç, ÀÌ ¶§¹®¿¡ ½Å°æ ´ÜÀ§ÀÇ ¹ÝÀÀ¼ºÀÌ °¨¾àµÈ´Ù.
  • inhibitory substantia gelatinosa cell
    ¾ïÁ¦¼º ±³¾çÁú ¼¼Æ÷
  • inhibitory synapse
    ¾ïÁ¦¼º ½Ã³³½º
  • light touch inhibitory
    ºÒºû ÀÚ±Ø ¾ïÁ¦
  • minimum inhibitory dose
    ÃÖ¼Ò ¾ïÁ¦·®
  • peripheral inhibitory field
    ¸»ÃÊ ¾ïÁ¦¾ß
  • presynaptic inhibitory action
    ½Ã³³½ºÀü ¾ïÁ¦ ÀÛ¿ë
  • A alpha
    A ¾ËÆÄ, A ¾ËÆÄ ½Å°æ ¼¶À¯
  • A alpha primary afferent
    A ¾ËÆÄ ÀÏÂ÷ ±¸½É ½Å°æ
    ±Ù¹æÃß ³»ÀÇ ±Ù ¼¶À¯¿¡ Á¸ÀçÇÏ´Â °¨°¢½Å°æÀÇ Çϳª·Î ¥°a °¨°¢ ½Å°æÀ̶ó°íµµ ÇÑ´Ù. Á÷°æÀº 22§­, Àüµµ ¼Óµµ´Â 120§½ÀÌ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
inhibitory synapse A synapse in which an action potential in the presynaptic cell reduces the probability of an action potential occurring in the postsynaptic cell. The most common inhibitory neurotransmitter is GABA, this opens channels in the postsynaptic cell which tend to stabilise its resting potential, thus rendering it less likely to fire.
See: excitatory synapse, presynaptic inhibition, postsynaptic inhibition.
(18 Nov 1997)
leukocyte migration-inhibitory factors Protein factor(s) released by sensitised lymphocytes (and possibly other cells) that inhibit the movement of leukocytes, especially polymorphonuclear cells, away from their site of release. Assays for these factors are used as tests for cellular immunity. Two of the common assays are the leukocyte migration capillary tube technique (lmct) and the leukocyte migration agarose technique (lmat).
(12 Dec 1998)
alpha, alpha-phosphotrehalase <enzyme> Forms glucose plus glucose-6-phosphate
Registry number: EC 3.2.1.93
Synonym: trehalose-6-phosphate hydrolase, phospho-alpha(1,1)glucosidase, trea gene product, trec gene product
(26 Jun 1999)
alpha,alpha-trehalose phosphorylase <enzyme> Chemical name: alpha-d-glucopyranosyl-alpha-d-glucopyranose orthophosphate glucosyltransferase
Registry number: EC 2.4.1.64
Synonym: trehalose phosphorylase
(26 Jun 1999)
alpha-dextrin endo-1,6-alpha-glucosidase <enzyme> An enzyme with action similar to that of isoamylase; it cleaves 1,6-alpha-glucosidic linkages in pullalan, amylopectin, and glycogen, and in alpha-and beta-amylase limit-dextrins of amylopectin and glycogen.
Compare: isoamylase.
Synonym: limit dextrinase, pullulanase, R enzyme.
(05 Mar 2000)
alpha-hydroxymethyl-alpha'-(N-acetylaminomethylene)succinic acid hydrolase <enzyme> Involved in degradation of vitamin b6; forms acetic acid plus ammonia plus carbon dioxide plus alpha-hydroxymethyl-succinic monoaldehyde
Registry number: EC 3.5.1.-
Synonym: compound b hydrolase
(26 Jun 1999)
cholesterol-5 alpha,6 alpha-epoxide hydrase <enzyme> Aspect of epoxide hydrolase, EC 3.3.2.3
Pharmacological action: carcinogen
Registry number: EC 3.3.2.-
Synonym: cholesterol epoxide hydrase, cholesterol epoxide hydrolase
(26 Jun 1999)
CMP-acetylneuraminate-alpha-N-acetylneuramide alpha-2,8-sialyltransferase <enzyme> Forms ganglioside gd3
Registry number: EC 2.4.99.8
Synonym: cmp-n-acetylneuraminate-gm3 sialyltransferase, gm3-sialosyltransferase, gd3 synthase, gd3-synthase, cmp-n-acetylneuraminate-(n-acetylneuraminyl)-d-galactosyl-d-glucosylceramide sialyltransferase, sialyltransferase II, st II, g(m3) alpha-2,8-sialyltransferase, st8sia I, stii enzyme, stiii enzyme, gt3 synthase
(26 Jun 1999)
CMP-N-acetylneuraminate-alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase <enzyme> Enzyme from foetal calf liver; forms branched tetrasaccharide, neuac-alpha2-3gal-beta1-3(neuac-alpha2-6)galnac of fetuin
Registry number: EC 2.4.99.3
Synonym: cmp-aag-sialyltransferase, st6galnaci, galnac 2,6-sialyltransferase
(26 Jun 1999)
NAD 3 alpha-hydroxy-5 alpha-pregnan-20-one-oxidoreductase <enzyme> From rat liver microsomes
Registry number: EC 1.1.1.-
Synonym: nad-3-hp-20-oor
(26 Jun 1999)
1,4-alpha-d-glucan 6-alpha-d-glucosyltransferase A glucosyltransferase that transfers an alpha-glucosyl residue in a 1,4-alpha-glucan to the primary hydroxyl group of glucose in a 1,4-alpha-glucan.
See: 1,4-alpha-d-glucan branching enzyme.
Synonym: oligoglucan-branching glycosyltransferase.
(05 Mar 2000)
1,4-alpha-glucan 6-alpha-glucosyltransferase <enzyme> From aspergillus niger and oryzae
Registry number: EC 2.4.1.24
(26 Jun 1999)
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid <chemical> A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of vasopressin and activation of phospholipase c.
Pharmacological action: vasoconstrictor agents.
Chemical name: 5-Heptenoic Acid, 7-(6-(3-Hydroxy-1-Ocentyl)-2-Oxabicyclo(2.2.1)hept-5-yl)-, (1R-(1alpha,4alpha,5 beta(Z),6alpha(1E,3S*)))-
(12 Dec 1998)
5 alpha-3 alpha-hydroxysteroid dehydrogenase <enzyme> Androsterone can be substrate
Registry number: EC 1.1.1.50
Synonym: 3 alpha-hydroxysteroid dehydrogenase, 3 alpha-hydroxysteroid oxidoreductase, 3 oc-hydroxysteroid dehydrogenase
(26 Jun 1999)
5 alpha-androstane-3 beta,17 beta-diol 6 alpha-hydroxylase <enzyme> Requires NADPH, found in rat prostatic microsomes
Registry number: EC 1.14.13.-
Synonym: artdl 6 alpha-hydroxylase
(26 Jun 1999)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • prime factor
    ¼ÒÀμö
  • releasing factor
    È£¸£¸ó ¹æÃâÀÎÀÚ
  • rheumatoid factor
    ·ù¸ÓƼÁòÀÎÀÚ(¸¸¼º °üÀý ·ù¸ÓƼÁò ȯÀÚÀÇ ÀÚ±â Ç×ü)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á